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Methods:
 
 Polymorphisms of the AGT, ACE (I/D) and AGTR1 (A1166C)
genes in patients and controls were analyzed using allele-specific PCR, and
PCR-rflp. 
 
Results: 
 
A total of 140 healthy subjects and 119 individuals with MI were
divided into two groups < 65 and > 65 years old. The evolution with age
showed that the AGT M allele (P < 0.001) and the ACE I allele (P < 0.05)
frequency decreased with age. The TT genotype frequency increased in
patients with MI > 65 years (OR =3.52; 95% CI; 3.12-5.54). The AA genotype
showed a similar behaviour (OR = 2.9; 95% CI; 1.11-5.6). The DD genotype
increased in the MI > 65 group (OR = 6.66; 95% CI; 2.02-21.9).  Serum ACE
activity was positively associated to age (r=0.38, p=0.000). Patients with DD
genotype > 65 years was significantly higher (119.7 ± 50.8 U/L) than in
patients with DD genotype < 65 years (96.9 ± 31.4 U/L, p=0.039).
 
Conclusions:
 
 The incidence of new cardiovascular disease continued to
increase after age 65 but was most often diagnosed at death. These findings
suggest that people aged 60 and older have a substantial amount of undiag-
nosed disease. We propose that the study of the allele frequency evolution in
an healthy population at different ages is essential to determine risk factors for
MI in case-control studies.
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Background:
 
 Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is an inherited heart disease caused predominantly by heterozygous Plako-
philin-2 (PKP2) mutations. However, few molecular studies have been per-
formed to ascertain their pathogenicity. PKP2 encodes two isoforms, the
longest (PKP2b) including the alternatively spliced exon 6, which is routinely
screened for molecular diagnosis, despite the absence of data on the cardiac
expression of PKP2 isoforms. This study addressed the pathogenicity of exon
6 mutations by focusing on a heterozygous missense p.Arg490Trp variant in
PKP2. 
 
Methods and results:
 
 The p.Arg490Trp variant of PKP2 was identified in two
unrelated ARVC probands and absent from 470 controls. In silico analysis sug-
gests that PKP2 exon 6 is an Alu-derived sequence with very low expression level.
Transcriptional and Western blot analysis confirmed that the exon 6 missing
PKP2a was the only clearly detectable isoform in all heart samples (four controls
and a proband). Moreover, in the proband's heart sample, the variant was not asso-
ciated with aberrant exon 6 splicing or mutant mRNA down-regulation. Finally,
we identified in this proband a heterozygous missense variant (p.Glu2343Lys) in
the desmoplakin gene likely to be the disease-causing mutation.
 
Conclusion:
 
 We demonstrated that only PKP2a is significantly expressed in
the heart. Our results strongly suggest that the p.Arg490Trp mutation and other
variants located in PKP2 exon 6 can not be considered as disease-causing muta-
tions and therefore that PKP2 exon 6 screening is useless in routine ARVC
molecular diagnosis. These results have important consequences for the interpre-
tation of PKP2 mutation screening and subsequent genetic counseling.
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Aim:
 
 A major risk of myocardial ischemia (MI) is the onset of ventricular
fibrillation (VF). Our study evaluated the effect of heart rate reduction (HRR)
induce by ivabradine (IVA), the first selective inhibitor of the pacemaker cur-
rent If, on the risk of onset of VF, and study the possible mechanisms
involved.
 
Methods:
 
 MI was induced in pigs by total occlusion of the anterior inter-
ventricular artery until onset of VF, which was assessed by the VF threshold
(VFT; protocol 1) or the time to onset of VF (TOF; protocol 2), with or
without IVA (0.25mg/kg, i.v.). Electrophysiological, 
hemodynamic parameters and ischemic area were assessed in these two proto-
cols. The impact of IVA was evaluated on: i) ultrastructure of mitochondria
(by electron microscopy) in protocol 1; ii) myocardial energetic status com-
pared with a ß-blocker, propranolol (PROP) in protocol 2; iii) regional myo-
cardial blood flow (RMBF) after 1 min-ischemia followed (without VF) by
reperfusion by positrons emission tomography in protocol 3. 
 
Results:
 
 IVA induced a significant HRR (~25%), increased the VFT and
the TOF. When compare to control, IVA prevented the apparition of mito-
chondrial alterations due to repetitive sequences of MI/VF and reperfusion.
IVA improved the RMBF during reperfusion (after 1 min-occlusion). Also, the
myocardial energetic status evaluated by the concentrations of high energy
phosphates, was in part preserved with IVA. All of these changes were corre-
lated with IVA-induced HRR and were not associated with modifications in
the dP/dtmax.
 
Conclusions:
 
 Our results showed that IVA decreases the risk of the onset
of ischemia-induced VF. This effect can be explained by a preservation of
ultrastructure of mitochondria, an improvement in the RMBF and a better con-
servation of myocardial energetic status. Although further work is needed to
determine the mechanisms underlying these effects, this might give a place of
choice to IVA in the prevention of ischemia-induced VF.
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Aim: 
 
The spontaneously hypertensive rat (SHR) is a model of hypertension
with a Cd36 gene defect, which develops left ventricular hypertrophy (LVH)
between 9 and 12 weeks. At 15 weeks, perfused SHR hearts display a reduced
capacity to use long chain fatty acids (LCFAs) but not carbohydrates (CHOs)
for energy production. In this study, we have further examined LCFA metab-
olism and its potential (dys)regulation in SHR hearts prior to LVH. 
 
Methods:
 
 SHR and control Wistar rat hearts (7 weeks) have been used for:
i) functional and metabolic phenotyping using 
 
ex vivo
 
 perfusion with 
 
13
 
C-
labeled substrates, ii) metabolic gene expression profiling using qPCR, iii)
studies of mechanisms regulating -oxydation (malonyl-CoA, AMPK) and of
the functional impact of the gene mutation in the LCFA transporter Cd36
(western blot, confocal microscopy, qPCR, gene analysis).
 
Results:
 
 Compared to controls, 7-week-old SHR hearts display a lower
contribution of LCFA (i.e. oleate) to oxidation (40%) and triglyceride (2.8-
fold) formation, which is associated with a compensatory increase in CHO
oxidation. These alterations cannot be explained by changes in metabolic gene
expression or common mechanisms regulating -oxidation. Western analyses
demonstrate that compared to controls, cardiac CD36 protein level is lower in
the SHR, while data from confocal microscopy indicate a similar intracellular
localization. Sequence alignment of Cd36 cDNA indicates non-synonymous
